{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:33:23Z","timestamp":1790930003471,"version":"4.1.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,10,25]],"date-time":"2007-10-25T00:00:00Z","timestamp":1193270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11064-007-9518-3","type":"journal-article","created":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T18:22:09Z","timestamp":1193250129000},"page":"691-707","source":"Crossref","is-referenced-by-count":128,"title":["Innovative Approaches for the Treatment of Depression: Targeting the HPA Axis"],"prefix":"10.1007","volume":"33","author":[{"given":"Fiona","family":"Thomson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Craighead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,25]]},"reference":[{"key":"9518_CR1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617\u2013627","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","volume":"53","author":"M Fava","year":"2003","unstructured":"Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649\u2013659","journal-title":"Biol Psychiatry"},{"key":"9518_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-3956(85)90068-8","volume":"19","author":"AF Schatzberg","year":"1985","unstructured":"Schatzberg AF, Rothschild AJ, Langlais PJ, Langlais PJ, Bird ED, Cole JO (1985) A corticosteroid\/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19:57\u201364","journal-title":"J Psychiatr Res"},{"key":"9518_CR4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/eje.0.1450165","volume":"145","author":"P Putignano","year":"2001","unstructured":"Putignano P, Dubini A, Toja P, Invitti C, Bonfanti S, Redaelli G, Zappulli D, Cavagnini F (2001) Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol 145:165\u2013171","journal-title":"Eur J Endocrinol"},{"key":"9518_CR5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0165-1781(02)00126-9","volume":"110","author":"RD Marshall","year":"2002","unstructured":"Marshall RD, Blanco C, Printz D, Liebowitz MR, Klein DF, Coplan J (2002) A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder Psychiatry Res 110:219\u2013230","journal-title":"Psychiatry Res"},{"key":"9518_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3956(01)00013-9","volume":"35","author":"AW Zobel","year":"2001","unstructured":"Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001) Cortisol response in the combined dexamethasone\/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 35:83\u201394","journal-title":"J Psychiatr Res"},{"key":"9518_CR7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1176\/ajp.156.6.949","volume":"156","author":"AW Zobel","year":"1999","unstructured":"Zobel AW, Yassouridis A, Frieboes RM, Holsboer F (1999) Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156:949\u2013951","journal-title":"Am J Psychiatry"},{"key":"9518_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0196-9781(84)90080-9","volume":"5","author":"FA Antoni","year":"1984","unstructured":"Antoni FA, Holmes MC, Makara GB, Karteszi M, Laszlo FA (1984) Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 5:519\u2013522","journal-title":"Peptides"},{"key":"9518_CR9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.6267699","volume":"213","author":"W Vale","year":"1981","unstructured":"Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394\u20131397","journal-title":"Science"},{"key":"9518_CR10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01752277","volume":"44","author":"HJ Karl","year":"1966","unstructured":"Karl HJ, Raith L (1966) Corticosterone secretion in humans. 3. Secretory rate of corticosterone and cortisol during stimulation of the adrenal cortex with ACTH. Klin Wochenschr 44:303\u2013306","journal-title":"Klin Wochenschr"},{"key":"9518_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/edrv-5-1-25","volume":"5","author":"A Munck","year":"1984","unstructured":"Munck A, Guyre PM, Holbrook NJ (1984) Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5:25\u201344","journal-title":"Endocr Rev"},{"key":"9518_CR12","first-page":"55","volume":"21","author":"RM Sapolsky","year":"2000","unstructured":"Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21:55\u201389","journal-title":"Endocr Rev"},{"key":"9518_CR13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0149-7634(03)00033-2","volume":"27","author":"K Erickson","year":"2003","unstructured":"Erickson K, Drevets W, Schulkin J (2003) Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neurosci Biobehav Rev 27:233\u2013246","journal-title":"Neurosci Biobehav Rev"},{"key":"9518_CR14","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1210\/endo-117-6-2505","volume":"117","author":"JM Reul","year":"1985","unstructured":"Reul JM, de Kloet ER (1985) Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117:2505\u20132511","journal-title":"Endocrinology"},{"key":"9518_CR15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0006-8993(90)90433-C","volume":"514","author":"RL Spencer","year":"1990","unstructured":"Spencer RL, Young EA, Choo PH, McEwen BS (1990) Adrenal steroid type I. and type II receptor binding: estimates of in\u00a0vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res 514:37\u201348","journal-title":"Brain Res"},{"key":"9518_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1749-6632.1994.tb39204.x","volume":"746","author":"ER Kloet de","year":"1994","unstructured":"de Kloet ER, Rots NY, Van den Berg DT, Oitzl MS (1994) Brain mineralocorticoid receptor function. Ann NY Acad Sci 746:8\u201320","journal-title":"Ann NY Acad Sci"},{"key":"9518_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/edrv-17-2-187","volume":"17","author":"F Holsboer","year":"1996","unstructured":"Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17:187\u2013205","journal-title":"Endocr Rev"},{"key":"9518_CR18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJM198808113190606","volume":"319","author":"PW Gold","year":"1988","unstructured":"Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med 319:348\u2013353","journal-title":"N Engl J Med"},{"key":"9518_CR19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1056\/NEJM198808183190706","volume":"319","author":"PW Gold","year":"1988","unstructured":"Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2). N Engl J Med 319:413\u2013420","journal-title":"N Engl J Med"},{"key":"9518_CR20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1176\/ajp.149.8.999","volume":"149","author":"RM Post","year":"1992","unstructured":"Post RM (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999\u20131010","journal-title":"Am J Psychiatry"},{"key":"9518_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S0033291700007480","volume":"6","author":"BJ Carroll","year":"1976","unstructured":"Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA (1976) Urinary free cortisol excretion in depression. Psychol Med 6:43\u201350","journal-title":"Psychol Med"},{"key":"9518_CR22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM198605223142101","volume":"314","author":"PW Gold","year":"1986","unstructured":"Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W (1986) Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing\u2019s disease. Pathophysiologic and diagnostic implications. N Engl J Med 314:1329\u20131335","journal-title":"N Engl J Med"},{"key":"9518_CR23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archpsyc.1985.01790320076010","volume":"42","author":"U Halbreich","year":"1985","unstructured":"Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS (1985) Cortisol secretion in endogenous depression. I. Basal plasma levels. Arch Gen Psychiatry 42:904\u2013908","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archpsyc.1985.01790320081011","volume":"42","author":"U Halbreich","year":"1985","unstructured":"Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS (1985) Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry 42:909\u2013914","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR25","first-page":"1127","volume":"311","author":"F Holsboer","year":"1984","unstructured":"Holsboer F, Von Bardeleben U, Gerken A, Stalla GK, Muller OA (1984) Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 311:1127","journal-title":"N Engl J Med"},{"key":"9518_CR26","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1126\/science.6334362","volume":"226","author":"CB Nemeroff","year":"1984","unstructured":"Nemeroff CB, Widerlov E, Bissette G. Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342\u20131344","journal-title":"Science"},{"key":"9518_CR27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archpsyc.1993.01820170073010","volume":"50","author":"EA Young","year":"1993","unstructured":"Young EA, Kotun J, Haskett RF, Grunhaus L, Greden JF, Watson SJ, Akil H (1993) Dissociation between pituitary and adrenal suppression to dexamethasone in depression. Arch Gen Psychiatry 50:395\u2013403","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0006-3223(89)90267-9","volume":"25","author":"RG Kathol","year":"1989","unstructured":"Kathol RG, Anton R, Noyes R, Gehris T (1989) Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry 25:873\u2013878","journal-title":"Biol Psychiatry"},{"key":"9518_CR29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/jcem.82.1.3689","volume":"82","author":"M Deuschle","year":"1997","unstructured":"Deuschle M, Schweiger U, Weber C, Gotthardt U, Korner A, Schmider J, Standhardt H, Lammers CH, Heuser I (1997) Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 82:234\u2013238","journal-title":"J Clin Endocrinol Metab"},{"key":"9518_CR30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archpsyc.1987.01800210019003","volume":"44","author":"JD Amsterdam","year":"1987","unstructured":"Amsterdam JD, Maislin G, Winokur A, Kling M, Gold P (1987) Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers. Arch Gen Psychiatry 44:775\u2013781","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S0033291703001004","volume":"34","author":"TG Dinan","year":"2004","unstructured":"Dinan TG, O\u2019Brien S, Lavelle E, Scott LV (2004) Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med 34:169\u2013172","journal-title":"Psychol Med"},{"key":"9518_CR32","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1176\/ajp.154.11.1497","volume":"154","author":"JC Nelson","year":"1997","unstructured":"Nelson JC, Davis JM (1997) DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 154:1497\u20131503","journal-title":"Am J Psychiatry"},{"key":"9518_CR33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archpsyc.1996.01830040059010","volume":"53","author":"JL Abelson","year":"1996","unstructured":"Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 53:323\u2013331","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR34","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1176\/ajp.154.5.624","volume":"154","author":"JD Bremner","year":"1997","unstructured":"Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624\u2013629","journal-title":"Am J Psychiatry"},{"key":"9518_CR35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jpsychires.2005.08.002","volume":"40","author":"CS Kloet de","year":"2006","unstructured":"de Kloet CS, Vermettenm E, Geuze E, Kavelaars A, Heijnen CJ, Westenberg HG (2006) Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res 40:550\u2013567","journal-title":"J Psychiatr Res"},{"key":"9518_CR36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archpsyc.1981.01780260017001","volume":"38","author":"BJ Carroll","year":"1981","unstructured":"Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young E (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38:15\u201322","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0006-3223(87)90237-X","volume":"22","author":"F Holsboer","year":"1987","unstructured":"Holsboer F, Von Bardeleben U, Wiedemann K, Muller OA, Stalla GK (1987) Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry 22:228\u2013234","journal-title":"Biol Psychiatry"},{"key":"9518_CR38","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/0006-3223(91)90360-X","volume":"29","author":"U Bardeleben Von","year":"1991","unstructured":"Von Bardeleben U, Holsboer F (1991) Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone. Biol Psychiatry 29:1042\u20131050","journal-title":"Biol Psychiatry"},{"key":"9518_CR39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0022-3956(94)90017-5","volume":"28","author":"I Heuser","year":"1994","unstructured":"Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone\/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28:341\u2013356","journal-title":"J Psychiatr Res"},{"key":"9518_CR40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000127275","volume":"65","author":"S Modell","year":"1997","unstructured":"Modell S, Yassouridis A, Huber J, Holsboer F (1997) Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65:216\u2013222","journal-title":"Neuroendocrinology"},{"key":"9518_CR41","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1523\/JNEUROSCI.0736-05.2005","volume":"25","author":"S Ridder","year":"2005","unstructured":"Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, Zink M, Hortnagl H, Flor H, Henn FA, Schutz G, Gass P (2005) Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 25:6243\u20136250","journal-title":"J Neurosci"},{"key":"9518_CR42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endo.133.1.8391426","volume":"133","author":"JM Reul","year":"1993","unstructured":"Reul JM, Stec I, Soder M, Holsboer F (1993) Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312\u2013320","journal-title":"Endocrinology"},{"key":"9518_CR43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000126788","volume":"60","author":"JM Reul","year":"1994","unstructured":"Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F (1994) Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60:509\u2013519","journal-title":"Neuroendocrinology"},{"key":"9518_CR44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF01250136","volume":"73","author":"I Kitayama","year":"1988","unstructured":"Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, Ogren SO, Harfstrand A, Eneroth P, Gustafsson JA (1988) Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. J Neural Transm 73:191\u2013203","journal-title":"J Neural Transm"},{"key":"9518_CR45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000126180","volume":"55","author":"JR Seckl","year":"1992","unstructured":"Seckl JR, Fink G (1992) Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in\u00a0vivo. Neuroendocrinology 55:621\u2013626","journal-title":"Neuroendocrinology"},{"key":"9518_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0169-328X(89)90031-4","volume":"6","author":"MC Pepin","year":"1989","unstructured":"Pepin MC, Beaulieu S, Barden N (1989) Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 6:77\u201383","journal-title":"Brain Res Mol Brain Res"},{"key":"9518_CR47","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1159\/000126778","volume":"60","author":"FC Raadsheer","year":"1994","unstructured":"Raadsheer FC, Hoogendijk WJ, Stam FC Tilders FJ, Swaab DF (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436\u2013444","journal-title":"Neuroendocrinology"},{"key":"9518_CR48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archpsyc.1992.01820010009002","volume":"49","author":"M Altemus","year":"1992","unstructured":"Altemus M, Pigott T, Kalogeras KT, Demitrack M, Dubbert B, Murphy DL, Gold PW (1992) Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 49:9\u201320","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(96)00312-5","volume":"42","author":"TD Geracioti Jr","year":"1997","unstructured":"Geracioti TD Jr, Loosen PT, Orth DN (1997) Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42:165\u2013174","journal-title":"Biol Psychiatry"},{"key":"9518_CR50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/jcem-72-2-260","volume":"72","author":"MA Kling","year":"1991","unstructured":"Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whitfield HJ Jr, May C, Post RM, Chrousos GP, Gold PW (1991) Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing\u2019s. disease and major depression: potential clinical implications. J Clin Endocrinol Metab 72:260\u2013271","journal-title":"J Clin Endocrinol Metab"},{"key":"9518_CR51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0006-3223(95)00229-A","volume":"38","author":"AF Pitts","year":"1995","unstructured":"Pitts AF, Samuelson SD, Meller WH, Bissette G, Nemeroff CB, Kathol RG (1995) Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol Psychiatry 38:330\u2013335","journal-title":"Biol Psychiatry"},{"key":"9518_CR52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-3956(98)90056-5","volume":"33","author":"F Holsboer","year":"1999","unstructured":"Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R.) antagonists to treat depression and anxiety. J Psychiatr Res 33:181\u2013214","journal-title":"J Psychiatr Res"},{"key":"9518_CR53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1988.01800300075009","volume":"45","author":"CB Nemeroff","year":"1988","unstructured":"Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577\u2013579","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1210\/jcem-69-3-600","volume":"69","author":"R Rupprecht","year":"1989","unstructured":"Rupprecht R, Lesch KP, Muller U, Beck G, Beckmann H, Schulte HM (1989) Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression. J Clin Endocrinol Metab 69:600\u2013603","journal-title":"J Clin Endocrinol Metab"},{"key":"9518_CR55","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.1994.03950100042004","volume":"51","author":"M Altemus","year":"1994","unstructured":"Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51:794\u2013803","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0924-977X(92)90019-5","volume":"2","author":"CM Banki","year":"1992","unstructured":"Banki CM, Karmacsi L, Bissette G, Nemeroff CB (1992) CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 2:107\u2013113","journal-title":"Eur Neuropsychopharmacol"},{"key":"9518_CR57","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1176\/ajp.150.4.656","volume":"150","author":"MD Bellis De","year":"1993","unstructured":"De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150:656\u2013657","journal-title":"Am J Psychiatry"},{"key":"9518_CR58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/bjp.158.1.59","volume":"158","author":"CB Nemeroff","year":"1991","unstructured":"Nemeroff CB, Bissette G, Akil H, Fink M (1991) Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158:59\u201363","journal-title":"Br J Psychiatry"},{"key":"9518_CR59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(92)90459-M","volume":"572","author":"LS Brady","year":"1992","unstructured":"Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr (1992) The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572:117\u2013125","journal-title":"Brain Res"},{"key":"9518_CR60","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1172\/JCI115086","volume":"87","author":"LS Brady","year":"1991","unstructured":"Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M (1991) Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 87:831\u2013837","journal-title":"J Clin Invest"},{"key":"9518_CR61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2826.1999.00362.x","volume":"11","author":"JB Jensen","year":"1999","unstructured":"Jensen JB, Jessop DS, Harbuz MS, Harbuz MS, Mork A, Sanchez C, Mikkelsen JD (1999) Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 11:465\u2013471","journal-title":"J Neuroendocrinol"},{"key":"9518_CR62","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.300.3.1085","volume":"300","author":"SC Stout","year":"2002","unstructured":"Stout SC, Owens MJ, Nemeroff CB (2002) Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300:1085\u20131092","journal-title":"J Pharmacol Exp Ther"},{"key":"9518_CR63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0893-133X(89)90007-9","volume":"2","author":"DE Grigoriadis","year":"1989","unstructured":"Grigoriadis DE, Pearsall D, De Souza EB (1989) Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary. Neuropsychopharmacology 2:53\u201360","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/15622970410029921","volume":"5","author":"HM Praag van","year":"2004","unstructured":"van Praag HM (2004) Let the facts prevail. World J Biol Psychiatry 5:116","journal-title":"World J Biol Psychiatry"},{"key":"9518_CR65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(02)03189-X","volume":"952","author":"EP Zorrilla","year":"2002","unstructured":"Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002) Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952:188\u2013199","journal-title":"Brain Res"},{"key":"9518_CR66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.1995.tb44670.x","volume":"771","author":"C Song","year":"1995","unstructured":"Song C, Earley C, Leonard BE (1995) Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress? Ann NY Acad Sci 771:55\u201372","journal-title":"Ann NY Acad Sci"},{"key":"9518_CR67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s002130050654","volume":"138","author":"DN Jones","year":"1998","unstructured":"Jones DN, Kortekaas R, Slade PD, Middlemiss DN, Hagan JJ (1998) The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology 138:124\u2013132","journal-title":"Psychopharmacology"},{"key":"9518_CR68","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1523\/JNEUROSCI.14-05-02579.1994","volume":"14","author":"MP Stenzel-Poore","year":"1994","unstructured":"Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW (1994) Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 14:2579\u20132584","journal-title":"J Neurosci"},{"key":"9518_CR69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0306-4530(97)00030-9","volume":"22","author":"SC Heinrichs","year":"1997","unstructured":"Heinrichs SC, Min H, Tamraz S, Carmouche M, Boehme SA, Vale WW (1997) Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22:215\u2013224","journal-title":"Psychoneuroendocrinology"},{"key":"9518_CR70","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1046\/j.1460-9568.2002.02040.x","volume":"15","author":"MM Gaalen van","year":"2002","unstructured":"van Gaalen MM, Stenzel-Poore MP, Holsboer F, Steckler T (2002) Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15:2007\u20132015","journal-title":"Eur J Neurosci"},{"key":"9518_CR71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0167-0115(95)00099-W","volume":"59","author":"G Liebsch","year":"1995","unstructured":"Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A (1995) Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 59:229\u2013239","journal-title":"Regul Pept"},{"key":"9518_CR72","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0896-6273(00)80491-2","volume":"20","author":"GW Smith","year":"1998","unstructured":"Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093\u20131102","journal-title":"Neuron"},{"key":"9518_CR73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/520","volume":"19","author":"P Timpl","year":"1998","unstructured":"Timpl P, Spanagel R, Sillaber I. Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat Genet 19:162\u2013166","journal-title":"Nat Genet"},{"key":"9518_CR74","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/nn1123","volume":"6","author":"MB Muller","year":"2003","unstructured":"Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kuhn R, Reul JM, Holsboer F, Wurst W (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100\u20131107","journal-title":"Nat Neurosci"},{"key":"9518_CR75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archpsyc.1996.01830020055007","volume":"53","author":"JS Purba","year":"1996","unstructured":"Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF (1996) Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 53:137\u2013143","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR76","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archpsyc.58.7.655","volume":"58","author":"JN Zhou","year":"2001","unstructured":"Zhou JN, Riemersma RF, Unmehopam UA Hoogendijk WJ, van Heerikhuize JJ, Hofman MA, Swaab DF (2001) Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 58:655\u2013662","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR77","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/sj.npp.1300002","volume":"28","author":"RF Winter de","year":"2003","unstructured":"de Winter RF, van Hemert AM, DeRijk RH, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM, Goekoop JG (2003) Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 28:140\u2013147","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR78","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0893-133X(97)00054-7","volume":"17","author":"L Londen van","year":"1997","unstructured":"van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, De Wied D (1997) Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17:284\u2013292","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0924-977X(02)00071-8","volume":"12","author":"J Brunner","year":"2002","unstructured":"Brunner J, Keck ME, Landgraf R, Uhr M, Namendorf C, Bronisch T (2002) Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results. Eur Neuropsychopharmacology 12:489\u2013494","journal-title":"Eur Neuropsychopharmacology"},{"key":"9518_CR80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/jnnp.48.1.50","volume":"48","author":"PS Sorensen","year":"1985","unstructured":"Sorensen PS, Gjerris A, Hammer M (1985) Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry 48:50\u201357","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9518_CR81","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1192\/bjp.147.6.696","volume":"147","author":"A Gjerris","year":"1985","unstructured":"Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ (1985) Cerebrospinal fluid vasopressin-changes in depression. Br J Psychiatry 147:696\u2013701","journal-title":"Br J Psychiatry"},{"key":"9518_CR82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0893-133X(00)00182-2","volume":"24","author":"JL Abelson","year":"2001","unstructured":"Abelson JL, Le Melledo J, Bichet DG (2001) Dose response of arginine vasopressin to the CCK-C agonist pentagastrin. Neuropsychopharmacology 24:161\u2013169","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR83","first-page":"151","volume-title":"Depressive illness: some research studies","author":"BJ Carroll","year":"1972","unstructured":"Carroll BJ (1972) Stimulation tests in depression. In: Davies B, Carroll BJ, Mowbray RM (eds) Depressive illness: some research studies. CC Thomas, Springfield, pp 151\u2013153"},{"key":"9518_CR84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/0006-3223(85)90217-3","volume":"20","author":"DD Krahn","year":"1985","unstructured":"Krahn DD, Meller WH, Shafer RB, Morley JE (1985) Cortisol response to vasopressin in depression. Biol Psychiatry 20:918\u2013921","journal-title":"Biol Psychiatry"},{"key":"9518_CR85","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1210\/jcem.84.6.5723","volume":"84","author":"TG Dinan","year":"1999","unstructured":"Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB (1999) Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 84:2238\u20132240","journal-title":"J Clin Endocrinol Metab"},{"key":"9518_CR86","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000124768","volume":"45","author":"MH Whitnall","year":"1987","unstructured":"Whitnall MH, Smyth D, Gainer H (1987) Vasopressin coexists in half of the corticotropin-releasing factor axons present in the external zone of the median eminence in normal rats. Neuroendocrinology 45:420\u2013424","journal-title":"Neuroendocrinology"},{"key":"9518_CR87","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1365-2826.1995.tb00734.x","volume":"7","author":"C Rabadan-Diehl","year":"1995","unstructured":"Rabadan-Diehl C, Lolait SJ, Aguilera G (1995) Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat. J Neuroendocrinol 7:903\u2013910","journal-title":"J Neuroendocrinol"},{"key":"9518_CR88","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000125302","volume":"50","author":"MH Whitnall","year":"1989","unstructured":"Whitnall MH (1989) Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons. Neuroendocrinology 50:702\u2013707","journal-title":"Neuroendocrinology"},{"key":"9518_CR89","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/endo-119-3-972","volume":"119","author":"AB Abou-Samra","year":"1986","unstructured":"Abou-Samra AB, Catt KJ, Aguilera G (1986) Biphasic inhibition of adrenocorticotropin release by corticosterone in cultured anterior pituitary cells. Endocrinology 119:972\u2013977","journal-title":"Endocrinology"},{"key":"9518_CR90","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1210\/mend-1-7-451","volume":"1","author":"LM Bilezikjian","year":"1987","unstructured":"Bilezikjian LM, Blount AL, Vale WW (1987) The cellular actions of vasopressin on corticotrophs of the anterior pituitary: resistance to glucocorticoid action. Mol Endocrinol 1:451\u2013458","journal-title":"Mol Endocrinol"},{"key":"9518_CR91","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0893-133X(01)00351-7","volume":"26","author":"ME Keck","year":"2002","unstructured":"Keck ME, Wigger A, Welt T, Muller MB, Gesing A, Reul JM, Holsboer F, Landgraf R, Neumann ID (2002) Vasopressin mediates the response of the combined dexamethasone\/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26:94\u2013105","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR92","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2826.1999.00342.x","volume":"11","author":"R Landgraf","year":"1999","unstructured":"Landgraf R, Wigger A, Holsboer F, Neumann ID (1999) Hyper-reactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behaviour. J Neuroendocrinol 11:405\u2013407","journal-title":"J Neuroendocrinol"},{"key":"9518_CR93","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-006-0424-1","volume":"187","author":"N Salome","year":"2006","unstructured":"Salome N, Stemmelin J, Cohen C, Griebel G (2006) Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology 187:237\u2013244","journal-title":"Psychopharmacology"},{"key":"9518_CR94","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1523\/JNEUROSCI.1614-04.2004","volume":"24","author":"C Murgatroyd","year":"2004","unstructured":"Murgatroyd C, Wigger A, Frank E, Singewald N, Bunck M, Holsboer F, Landgraf R, Spengler D (2004) Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 24:7762\u20137770","journal-title":"J Neurosci"},{"key":"9518_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.npp.1300290","volume":"29","author":"A Wigger","year":"2004","unstructured":"Wigger A, Sanchez MM, Mathys KC, Ebner K, Frank E, Liu D, Kresse A, Neumann ID, Holsboer F, Plotsky PM, Landgraf R (2004) Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 29:1\u201314","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.npp.1300040","volume":"28","author":"ME Keck","year":"2003","unstructured":"Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R (2003) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28:235\u2013243","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR97","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152706776359664","volume":"5","author":"R Landgraf","year":"2006","unstructured":"Landgraf R (2006) The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 5:167\u2013179","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"9518_CR98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cne.902610206","volume":"261","author":"AR Caffe","year":"1987","unstructured":"Caffe AR, van Leeuwen FW, Luiten PG (1987) Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J Comp Neurol 261:237\u2013252","journal-title":"J Comp Neurol"},{"key":"9518_CR99","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-8993(83)90855-7","volume":"273","author":"GJ Vries De","year":"1983","unstructured":"De Vries GJ, Buijs RM (1983) The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res 273:307\u2013317","journal-title":"Brain Res"},{"key":"9518_CR100","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1523\/JNEUROSCI.16-23-07725.1996","volume":"16","author":"CT Wotjak","year":"1996","unstructured":"Wotjak CT, Kubota M, Liebsch G, Montkowski A, Holsboer F, Neumann I, Landgraf R (1996) Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion?. J Neurosci 16:7725\u20137732","journal-title":"J Neurosci"},{"key":"9518_CR101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-8993(00)02464-1","volume":"872","author":"K Ebner","year":"2000","unstructured":"Ebner K, Wotjak CT, Landgraf R, Engelmann M (2000) A single social defeat experience selectively stimulates the release of oxytocin, but not vasopressin, within the septal brain area of male rats. Brain Res 872:87\u201392","journal-title":"Brain Res"},{"key":"9518_CR102","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1046\/j.1460-9568.1999.00508.x","volume":"11","author":"K Ebner","year":"1999","unstructured":"Ebner K, Wotjak CT, Holsboer F, Engelmann M (1999) Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Eur J Neurosci 11:997\u20131002","journal-title":"Eur J Neurosci"},{"key":"9518_CR103","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0306-4522(97)00683-0","volume":"85","author":"CT Wotjak","year":"1998","unstructured":"Wotjak CT, Ganster J, Kohl G, Holsboer F, Landgraf R, Engelmann M (1998) Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience 85:1209\u20131222","journal-title":"Neuroscience"},{"key":"9518_CR104","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/endo.142.4.8067","volume":"142","author":"F Hernando","year":"2001","unstructured":"Hernando F, Schoots O, Lolait SJ, Burbach JP (2001) Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142:1659\u20131668","journal-title":"Endocrinology"},{"key":"9518_CR105","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuroscience.2006.08.040","volume":"143","author":"WS Young","year":"2006","unstructured":"Young WS, Li J, Wersinger SR, Palkovits M (2006) The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience 143:1031\u20131039","journal-title":"Neuroscience"},{"key":"9518_CR106","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/sj.mp.4001195","volume":"7","author":"SR Wersinger","year":"2002","unstructured":"Wersinger SR, Ginns EI, O\u2019Carroll AM, Lolait SJ, Young WS III (2002) Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 7:975\u2013984","journal-title":"Mol Psychiatry"},{"key":"9518_CR107","doi-asserted-by":"crossref","first-page":"E147","DOI":"10.1152\/ajpendo.00005.2006","volume":"291","author":"S Itoh","year":"2006","unstructured":"Itoh S, Yamada S, Mori T, Miwa T, Tottori K, Uwahodo Y, Yamamura Y, Fukuda M, Yamamoto K, Tanoue A, Tsujimoto G (2006) Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor. Am J Physiol Endocrinol Metab 291:E147\u2013E151","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"9518_CR108","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.yhbeh.2004.07.004","volume":"46","author":"SR Wersinger","year":"2004","unstructured":"Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O\u2019Carroll AM, Young WS III (2004) Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav 46:638\u2013645","journal-title":"Horm Behav"},{"key":"9518_CR109","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1172\/JCI200419656","volume":"113","author":"A Tanoue","year":"2004","unstructured":"Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 113:302\u2013309","journal-title":"J Clin Invest"},{"key":"9518_CR110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1210\/en.2006-1309","volume":"148","author":"SJ Lolait","year":"2007","unstructured":"Lolait SJ, Stewart LQ, Jessop DS, Young WS III, O\u2019Carroll AM (2007) The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 148:849\u2013856","journal-title":"Endocrinology"},{"key":"9518_CR111","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.psyneuen.2005.03.005","volume":"30","author":"S Het","year":"2005","unstructured":"Het S, Ramlow G, Wolf OT (2005) A meta-analytic review of the effects of acute cortisol administration on human memory. Psychoneuroendocrinology 30:771\u2013784","journal-title":"Psychoneuroendocrinology"},{"key":"9518_CR112","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1006\/nlme.2002.4080","volume":"78","author":"C Roozendaal","year":"2002","unstructured":"Roozendaal C (2002) Stress and memory: opposing effects of glucocorticoids on memory consolidation and memory retrieval. Neurobiol Learn Mem 78:578\u2013595","journal-title":"Neurobiol Learn Mem"},{"key":"9518_CR113","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00006842-200111000-00018","volume":"63","author":"MN Starkman","year":"2001","unstructured":"Starkman MN, Giordani C, Berent S, Schork MA, Schteingart DE (2001) Elevated cortisol levels in Cushing\u2019s. disease are associated with cognitive decrements. Psychosom Med 63:985\u2013993","journal-title":"Psychosom Med"},{"key":"9518_CR114","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00023210-200115050-00003","volume":"15","author":"N Sonino","year":"2001","unstructured":"Sonino N, Fava GA (2001) Psychiatric disorders associated with Cushing\u2019s. syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15:361\u2013373","journal-title":"CNS Drugs"},{"key":"9518_CR115","first-page":"912","volume":"82","author":"LD Dorn","year":"1997","unstructured":"Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP (1997) The longitudinal course of psychopathology in Cushing\u2019s. syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82:912\u2013919","journal-title":"J Clin Endocrinol Metab"},{"key":"9518_CR116","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1073\/pnas.93.9.3908","volume":"93","author":"YI Sheline","year":"1996","unstructured":"Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996) Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93:3908\u20133913","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"9518_CR117","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0006-3223(92)90079-F","volume":"32","author":"MN Starkman","year":"1992","unstructured":"Starkman MN, Gebarski SS, Berent S et\u00a0al (1992) Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing\u2019s. syndrome. Biol Psychiatry 32(9):756\u2013765","journal-title":"Biol Psychiatry"},{"key":"9518_CR118","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0006-3223(99)00203-6","volume":"46","author":"MN Starkman","year":"1999","unstructured":"Starkman MN, Giordani C, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999) Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing\u2019s. disease. Biol Psychiatry 46:1595\u20131602","journal-title":"Biol Psychiatry"},{"key":"9518_CR119","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0006-3223(99)00247-4","volume":"46","author":"E Gould","year":"1999","unstructured":"Gould E, Tanapat P (1999) Stress and hippocampal neurogenesis. Biol Psychiatry 46:1472\u20131479","journal-title":"Biol Psychiatry"},{"key":"9518_CR120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0006-8993(98)00218-2","volume":"794","author":"N Sousa","year":"1998","unstructured":"Sousa N, Madeira MD, Paula-Barbosa MM (1998) Effects of corticosterone treatment and rehabilitation on the hippocampal formation of neonatal and adult rats. An unbiased stereological study. Brain Res 794:199\u2013210","journal-title":"Brain Res"},{"key":"9518_CR121","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.wnr.0000221827.03222.70","volume":"17","author":"H Chen","year":"2006","unstructured":"Chen H, Pandey GN, Dwivedi Y (2006) Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 17:863\u2013867","journal-title":"Neuroreport"},{"key":"9518_CR122","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0031-9384(01)00497-8","volume":"73","author":"E Fuchs","year":"2001","unstructured":"Fuchs E, Flugge G, Ohl F, Lucassen P, Vollmann-Honsdorf GK, Michaelis T (2001) Psychosocial stress, glucocorticoids, and structural alterations in the tree shrew hippocampus. Physiol Behav 73:285\u2013291","journal-title":"Physiol Behav"},{"key":"9518_CR123","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neurobiolaging.2005.02.014","volume":"27","author":"MF Montaron","year":"2006","unstructured":"Montaron MF, Drapeau E, Dupret D, Kitchener P, Aurousseau C, Le Moal M, Piazza PV, Abrous DN (2006) Lifelong corticosterone level determines age-related decline in neurogenesis and memory. Neurobiol Aging 27:645\u2013654","journal-title":"Neurobiol Aging"},{"key":"9518_CR124","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.mp.4001679","volume":"10","author":"C Crochemore","year":"2005","unstructured":"Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, Almeida OF (2005) Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10:790\u2013798","journal-title":"Mol Psychiatry"},{"key":"9518_CR125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.psyneuen.2003.10.009","volume":"29","author":"CM Pariante","year":"2004","unstructured":"Pariante CM, Thomas SA, Lovestone S, Makoof A, Kerwin RW (2004) Do antidpressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29:423\u2013447","journal-title":"Psychoneuroendocrinology"},{"key":"9518_CR126","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1210\/endo.142.6.8213","volume":"142","author":"AM Karssen","year":"2001","unstructured":"Karssen AM, Meijer OC, van der Sandt IC, Lucassen PJ, de Lange EC, de Boer AG, de Kloet ER (2001) Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142:2686\u20132694","journal-title":"Endocrinology"},{"key":"9518_CR127","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","volume":"36","author":"AH Schinkel","year":"1999","unstructured":"Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood\u2013brain barrier. Adv Drug Deliv Rev 36:179\u2013194","journal-title":"Adv Drug Deliv Rev"},{"key":"9518_CR128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.bjp.0705357","volume":"139","author":"CM Pariante","year":"2003","unstructured":"Pariante CM, Kim RB, Makoff A, Kerwin RW (2003) Antidepressant fluoxetine enhances glucocorticoid receptor function in\u00a0vitro by modulating membrane steroid transporters. Br J Pharmacol 139:1111\u20131118","journal-title":"Br J Pharmacol"},{"key":"9518_CR129","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/sj.npp.1300195","volume":"28","author":"CM Pariante","year":"2003","unstructured":"Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW (2003) The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28:1553\u20131561","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0165-1781(91)90041-M","volume":"38","author":"E Holsboer-Trachsler","year":"1991","unstructured":"Holsboer-Trachsler E, Stohler R, Hatzinger M (1991) Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 38:163\u2013171","journal-title":"Psychiatry Res"},{"key":"9518_CR131","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0306-4530(97)00021-8","volume":"22","author":"BE Murphy","year":"1997","unstructured":"Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22:S125\u2013S132","journal-title":"Psychoneuroendocrinology"},{"key":"9518_CR132","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0960-0760(91)90069-H","volume":"39","author":"BE Murphy","year":"1991","unstructured":"Murphy BE (1991) Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol 39:239\u2013244","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9518_CR133","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/070674379804300307","volume":"43","author":"BE Murphy","year":"1998","unstructured":"Murphy BE, Ghadirian AM, Dhar V (1998) Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry 43:279\u2013286","journal-title":"Can J Psychiatry"},{"key":"9518_CR134","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0165-0327(94)00082-K","volume":"33","author":"AM O\u2019Dwyer","year":"1995","unstructured":"O\u2019Dwyer AM, Lightman SL, Marks MN, Checkley SA (1995) Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 33:123\u2013128","journal-title":"J Affect Disord"},{"key":"9518_CR135","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0006-3223(94)00137-R","volume":"37","author":"JH Thakore","year":"1995","unstructured":"Thakore JH, Dinan TG (1995) Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 37:364\u2013368","journal-title":"Biol Psychiatry"},{"key":"9518_CR136","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1176\/ajp.150.5.810","volume":"150","author":"OM Wolkowitz","year":"1993","unstructured":"Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H (1993) Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 150:810\u2013812","journal-title":"Am J Psychiatry"},{"key":"9518_CR137","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0924-977X(00)00105-X","volume":"10","author":"H Cohen","year":"2000","unstructured":"Cohen H, Benjamin J, Kaplan Z, Kotler M (2000) Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model. Eur Neuropsychopharmacol 10:429\u2013435","journal-title":"Eur Neuropsychopharmacol"},{"key":"9518_CR138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(85)90290-0","volume":"119","author":"GA Kennett","year":"1985","unstructured":"Kennett GA, Dickinson SL, Curzon G (1985) Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol 119:143\u2013152","journal-title":"Eur J Pharmacol"},{"key":"9518_CR139","first-page":"49","volume":"56","author":"Z Rogoz","year":"2005","unstructured":"Rogoz Z, Budziszewska C, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lason W (2005) Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 56:49\u201361","journal-title":"J Physiol Pharmacol"},{"key":"9518_CR140","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archpsyc.61.12.1235","volume":"61","author":"H Jahn","year":"2004","unstructured":"Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 61:1235\u20131244","journal-title":"Arch Gen Psychiatry"},{"key":"9518_CR141","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0889-8529(18)30100-2","volume":"23","author":"PC White","year":"1994","unstructured":"White PC, Speiser PW (1994) Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am 23:325\u2013339","journal-title":"Endocrinol Metab Clin North Am"},{"key":"9518_CR142","first-page":"S107","volume":"78","author":"M Craighead","year":"2004","unstructured":"Craighead M, Macdonald S, Hilier A, Speake M, Thomson F, Turnbull Z, Watson L (2004) Org 34850 is a potent antagonist of the glucorticoid receptor, in\u00a0vivo and in\u00a0vitro. J Affect Disord 78:S107","journal-title":"J Affect Disord"},{"key":"9518_CR143","first-page":"S138","volume":"78","author":"F Thomson","year":"2004","unstructured":"Thomson F, Broekkamp C, Craighead M, Eason S, Hilier A, Peeters C, Speake M, Watson L (2004) In\u00a0vivo and in\u00a0vitro charterisation of the glucocorticoid receptor antagonist Org 34517. J Affect Disord 78:S138","journal-title":"J Affect Disord"},{"key":"9518_CR144","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2826.2006.01455.x","volume":"18","author":"JL Mayer","year":"2006","unstructured":"Mayer JL, Klumpers L, Maslam S, de Kloet ER, Joels M, Lucassen PJ (2006) Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J Neuroendocrinol 18:629\u2013631","journal-title":"J Neuroendocrinol"},{"key":"9518_CR145","doi-asserted-by":"crossref","unstructured":"Spiga F, Harrison LR, Wood SA, Atkinson HC, MacSweeney C, Lightman SL (2006) Sub-chronic treatment with the glucocorticoid receptor antagonist Org 34850 increases basal HPA axis activity in rats. ISPNE Congress 2006, Leiden, The Netherlands","DOI":"10.1016\/j.yfrne.2006.03.113"},{"key":"9518_CR146","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/sj.npp.1300158","volume":"28","author":"CG Bachmann","year":"2003","unstructured":"Bachmann CG, Linthorst AC, Holsboer F, Reul JM (2003) Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 28:1056\u20131067","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR147","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000124900","volume":"47","author":"ER Kloet de","year":"1988","unstructured":"de Kloet ER, De Kock S, Schild V, Veldhuis HD (1988) Antiglucocorticoid RU 38486 attenuates retention of a behaviour and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites. Neuroendocrinology 47:109\u2013115","journal-title":"Neuroendocrinology"},{"key":"9518_CR148","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1460-9568.2005.04358.x","volume":"22","author":"A Bilang-Bleuel","year":"2005","unstructured":"Bilang-Bleuel A, Ulbricht S, Chandramohan Y, De Carli S, Droste SK, Reul JM (2005) Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response. Eur J Neurosci 22:1691\u20131700","journal-title":"Eur J Neurosci"},{"key":"9518_CR149","unstructured":"Smith LH, Erdemli G, Grassie M (2005) Central action of glucocorticoid receptor antagonists. ISPNE Congress 2005, Montreal, Canada"},{"key":"9518_CR150","unstructured":"Smith LH, Erdemli G, Grassie M (2005) Central action of glucocorticoid receptor antagonists. BAP Congress 2005, Harrogate, UK"},{"key":"9518_CR151","doi-asserted-by":"crossref","first-page":"143","DOI":"10.7326\/0003-4819-114-2-143","volume":"114","author":"AJ Lely van der","year":"1991","unstructured":"van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW (1991) Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 114:143\u2013144","journal-title":"Ann Intern Med"},{"key":"9518_CR152","first-page":"S148","volume":"5","author":"OJ Hoyberg","year":"2002","unstructured":"Hoyberg OJ, Wijk G, Mehtonen OP, Peeters BWMM, Senneff C (2002) Org 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: First clinical results. Int J Neuropsychopharmacol 5:S148","journal-title":"Int J Neuropsychopharmacol"},{"key":"9518_CR153","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00004714-200110000-00009","volume":"21","author":"JK Belanoff","year":"2001","unstructured":"Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF (2001) Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21:516\u2013521","journal-title":"J Clin Psychopharmacol"},{"key":"9518_CR154","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.biopsych.2006.05.034","volume":"60","author":"C DeBattista","year":"2006","unstructured":"DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G (2006) Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 60:1343\u20131349","journal-title":"Biol Psychiatry"},{"key":"9518_CR155","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/sj.npp.1300471","volume":"29","author":"AH Young","year":"2004","unstructured":"Young AH, Gallagher P, Watson S, Del Estal D, Owen BM, Ferrier IN (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29:1538\u20131545","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR156","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biopsych.2004.10.017","volume":"57","author":"P Gallagher","year":"2005","unstructured":"Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry 57:155\u2013161","journal-title":"Biol Psychiatry"},{"key":"9518_CR157","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/jcem-71-6-1474","volume":"71","author":"L Laue","year":"1990","unstructured":"Laue L, Lotze MT, Chrousos GP, Barnes K, Loriaux DL, Fleisher TA (1990) Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects J Clin Endocrinol Metab 71:1474\u20131480","journal-title":"J Clin Endocrinol Metab"},{"key":"9518_CR158","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1517\/13543784.13.7.799","volume":"13","author":"EP Zorrilla","year":"2004","unstructured":"Zorrilla EP, Koob GF (2004) The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13:799\u2013828","journal-title":"Expert Opin Investig Drugs"},{"key":"9518_CR159","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2004.07.091","volume":"499","author":"DM Nielsen","year":"2004","unstructured":"Nielsen DM, Carey GJ, Gold LH (2004) Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499:135\u2013146","journal-title":"Eur J Pharmacol"},{"key":"9518_CR160","unstructured":"Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P (2004) Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 9:278\u2013286, 224"},{"key":"9518_CR161","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.0953-816X.2000.01383.x","volume":"13","author":"ME Keck","year":"2001","unstructured":"Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R (2001) The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373\u2013380","journal-title":"Eur J Neurosci"},{"key":"9518_CR162","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1124\/jpet.102.042788","volume":"304","author":"DA Gutman","year":"2003","unstructured":"Gutman DA, Owens MJ, Skelton KH, Thrivikraman KV, Nemeroff CB (2003) The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304:874\u2013880","journal-title":"J Pharmacol Exp Ther"},{"key":"9518_CR163","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00213-004-2134-x","volume":"180","author":"A Post","year":"2005","unstructured":"Post A, Ohl F, Almeida OF, Binder EB, Rucker M, Welt S, Binder E, Holsboer F, Sillaber I (2005) Identification of molecules potentially involved in mediating the in\u00a0vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychopharmacology 180:150\u2013158","journal-title":"Psychopharmacology"},{"key":"9518_CR164","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-3565(24)36621-2","volume":"281","author":"AL Curtis","year":"1997","unstructured":"Curtis AL, Lechner SM, Pavcovich LA, Valentino RJ (1997) Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J Pharmacol Exp Ther 281:163\u2013172","journal-title":"J Pharmacol Exp Ther"},{"key":"9518_CR165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(03)01383-9","volume":"464","author":"F Lejeune","year":"2003","unstructured":"Lejeune F, Millan MJ (2003) The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats. Eur J Pharmacol 464:127\u2013133","journal-title":"Eur J Pharmacol"},{"key":"9518_CR166","doi-asserted-by":"crossref","first-page":"10477","DOI":"10.1073\/pnas.93.19.10477","volume":"93","author":"DW Schulz","year":"1996","unstructured":"Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD III, Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477\u201310482","journal-title":"Proc Natl Acad Sci USA"},{"key":"9518_CR167","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.npp.1300267","volume":"28","author":"A Oshima","year":"2003","unstructured":"Oshima A, Flachskamm C, Reul JM, Holsboer F, Linthorst AC (2003) Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775. Neuropsychopharmacology 28:2148\u20132159","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR168","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3956(00)00016-9","volume":"34","author":"AW Zobel","year":"2000","unstructured":"Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171\u2013181","journal-title":"J Psychiatr Res"},{"key":"9518_CR169","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3956(03)00076-1","volume":"38","author":"K Held","year":"2004","unstructured":"Held K, Kunzel H, Ising M, Schmid DA, Zobel A, Murck H, Holsboer F, Steiger A (2004) Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 38:129\u2013136","journal-title":"J Psychiatr Res"},{"key":"9518_CR170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jpsychires.2004.06.006","volume":"39","author":"HE Kunzel","year":"2005","unstructured":"Kunzel HE, Ising M, Zobel AW, Nickel T, Ackl N, Sonntag A, Holsboer F, Uhr M (2005) Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. J Psychiatr Res 39:173\u2013177","journal-title":"J Psychiatr Res"},{"key":"9518_CR171","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0022-3956(03)00070-0","volume":"37","author":"HE Kunzel","year":"2003","unstructured":"Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37:525\u2013533","journal-title":"J Psychiatr Res"},{"key":"9518_CR172","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1568007033482850","volume":"2","author":"G Griebel","year":"2003","unstructured":"Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R (2003) The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2:191\u2013200","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"9518_CR173","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.bjp.0706383","volume":"146","author":"C Griffante","year":"2005","unstructured":"Griffante C, Green A, Curcuruto O, Haslam CP, Dickinson BA, Arban R (2005) Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b\/oxytocin receptor antagonist. Br J Pharmacol 146:744\u2013751","journal-title":"Br J Pharmacol"},{"key":"9518_CR174","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/jpet.300.3.1122","volume":"300","author":"C Serradeil-Le Gal","year":"2002","unstructured":"Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrie P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N.,N.-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300:1122\u20131130","journal-title":"J Pharmacol Exp Ther"},{"key":"9518_CR175","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/jpet.301.1.333","volume":"301","author":"G Griebel","year":"2002","unstructured":"Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrie P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N.-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333\u2013345","journal-title":"J Pharmacol Exp Ther"},{"key":"9518_CR176","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.06.032","volume":"543","author":"T Shimazaki","year":"2006","unstructured":"Shimazaki T, Iijima M, Chaki S (2006) The pituitary mediates the anxiolytic-like effects of the vasopressin V1b receptor antagonist, SSR149415, in a social interaction test in rats. Eur J Pharmacol 543:63\u201367","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9518_CR177","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.npp.1300562","volume":"30","author":"J Stemmelin","year":"2005","unstructured":"Stemmelin J, Lukovic L, Salome N, Griebel G (2005) Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30(1):35\u201342","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR178","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","volume":"99","author":"G Griebel","year":"2002","unstructured":"Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370\u20136375","journal-title":"Proc Natl Acad Sci USA"},{"key":"9518_CR179","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2007-1019504","volume":"15","author":"BJ Carroll","year":"1982","unstructured":"Carroll BJ (1982) Clinical applications of the dexamethasone supprssion test for endogenous depression. Pharmacopsychiatria 15:19\u201325","journal-title":"Pharmacopsychiatria"},{"key":"9518_CR180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0306-4530(02)00146-4","volume":"29","author":"BM Kudielka","year":"2004","unstructured":"Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C (2004) HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology 29:83\u201398","journal-title":"Psychoneuroendocrinology"},{"key":"9518_CR181","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0447.1990.tb05465.x","volume":"81","author":"JH Meador-Woodruff","year":"1990","unstructured":"Meador-Woodruff JH, Greden JF, Grunhaus L, Haskett RF (1990) Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: identification of contributing factors. Acta Psychiatr Scand 81:364\u2013371","journal-title":"Acta Psychiatr Scand"},{"key":"9518_CR182","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/sj.npp.1300676","volume":"30","author":"C Otte","year":"2005","unstructured":"Otte C, Lenoci M, Metzler T, Yehuda R, Marmar CR, Neylan TC (2005) Hypothalamic-pituitary-adrenal axis activity and sleep in posttraumatic stress disorder. Neuropsychopharmacology 30:1173\u20131180","journal-title":"Neuropsychopharmacology"},{"key":"9518_CR183","first-page":"233","volume":"15","author":"TE Seeman","year":"1994","unstructured":"Seeman TE, Robbins RJ (1994) Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocr Rev 15:233\u2013260","journal-title":"Endocr Rev"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-007-9518-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-007-9518-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-007-9518-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T21:38:59Z","timestamp":1737495539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-007-9518-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,25]]},"references-count":183,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["9518"],"URL":"https:\/\/doi.org\/10.1007\/s11064-007-9518-3","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,25]]}}}